Report Detail
Global (United States, European Union and China) Human Respiratory Syncytial Virus Drugs Market Research Report 2019-2025
- RnM3641545 |
- 02 August, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period.
The active participation of emerging economies toward research and development will drive the growth prospects for the market during the forecast period. The increasing R&D activities in emerging economies for RSV infection and its causes will fuel the development of novel drugs. One of the major factors responsible for the market’s growth is the rising amount of patented therapies for RSV treatment that result in substantial R&D activities from various big pharma companies and research institutes. For instance, in June 2016, the Lancet Respiratory Medicine reported that RSV was the most commonly detected pathogen linked with pneumonia among children in South Africa. Such new findings will increase the scope of anti-RSV drugs in new applications, such as pneumonia.
ROW accounted for the maximum market share during 2017 and continue to dominate the market for the next few years. One of the major factors responsible for the market’s growth in the region is the growing incidence of RSV infections in ROW, including the BRIC nations.
In 2019, the market size of Human Respiratory Syncytial Virus Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Human Respiratory Syncytial Virus Drugs.
This report studies the global market size of Human Respiratory Syncytial Virus Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Human Respiratory Syncytial Virus Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
...
Market Segment by Product Type
Approved Drugs
Off-Label Drugs
Market Segment by Application
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories Hospitals
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Human Respiratory Syncytial Virus Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Human Respiratory Syncytial Virus Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Human Respiratory Syncytial Virus Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Human Respiratory Syncytial Virus Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Approved Drugs
- 1.3.3 Off-Label Drugs
- 1.4 Market Segment by Application
- 1.4.1 Global Human Respiratory Syncytial Virus Drugs Market Share by Application (2019-2025)
- 1.4.2 Clinical Diagnostic
- 1.4.3 Laboratories Physicians' Office
- 1.4.4 Laboratories Hospitals
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Human Respiratory Syncytial Virus Drugs Market Size
- 2.1.1 Global Human Respiratory Syncytial Virus Drugs Revenue 2014-2025
- 2.1.2 Global Human Respiratory Syncytial Virus Drugs Sales 2014-2025
- 2.2 Human Respiratory Syncytial Virus Drugs Growth Rate by Regions
- 2.2.1 Global Human Respiratory Syncytial Virus Drugs Sales by Regions 2014-2019
- 2.2.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Human Respiratory Syncytial Virus Drugs Sales by Manufacturers
- 3.1.1 Human Respiratory Syncytial Virus Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Human Respiratory Syncytial Virus Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Human Respiratory Syncytial Virus Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Human Respiratory Syncytial Virus Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Human Respiratory Syncytial Virus Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Human Respiratory Syncytial Virus Drugs Price by Manufacturers
- 3.4 Key Manufacturers Human Respiratory Syncytial Virus Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Human Respiratory Syncytial Virus Drugs Market
- 3.6 Key Manufacturers Human Respiratory Syncytial Virus Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Approved Drugs Sales and Revenue (2014-2019)
- 4.1.2 Off-Label Drugs Sales and Revenue (2014-2019)
- 4.2 Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Type
- 4.3 Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Type
- 4.4 Human Respiratory Syncytial Virus Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Human Respiratory Syncytial Virus Drugs Sales by Application
6 United States
- 6.1 United States Human Respiratory Syncytial Virus Drugs Breakdown Data by Company
- 6.2 United States Human Respiratory Syncytial Virus Drugs Breakdown Data by Type
- 6.3 United States Human Respiratory Syncytial Virus Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Human Respiratory Syncytial Virus Drugs Breakdown Data by Company
- 7.2 European Union Human Respiratory Syncytial Virus Drugs Breakdown Data by Type
- 7.3 European Union Human Respiratory Syncytial Virus Drugs Breakdown Data by Application
8 China
- 8.1 China Human Respiratory Syncytial Virus Drugs Breakdown Data by Company
- 8.2 China Human Respiratory Syncytial Virus Drugs Breakdown Data by Type
- 8.3 China Human Respiratory Syncytial Virus Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Human Respiratory Syncytial Virus Drugs Breakdown Data by Company
- 9.2 Rest of World Human Respiratory Syncytial Virus Drugs Breakdown Data by Type
- 9.3 Rest of World Human Respiratory Syncytial Virus Drugs Breakdown Data by Application
- 9.4 Rest of World Human Respiratory Syncytial Virus Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Human Respiratory Syncytial Virus Drugs Sales by Countries
- 9.4.2 Rest of World Human Respiratory Syncytial Virus Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 AstraZeneca
- 10.1.1 AstraZeneca Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Human Respiratory Syncytial Virus Drugs
- 10.1.4 Human Respiratory Syncytial Virus Drugs Product Introduction
- 10.1.5 AstraZeneca Recent Development
- 10.2 AbbVie
- 10.2.1 AbbVie Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Human Respiratory Syncytial Virus Drugs
- 10.2.4 Human Respiratory Syncytial Virus Drugs Product Introduction
- 10.2.5 AbbVie Recent Development
- 10.3 GSK
- 10.3.1 GSK Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Human Respiratory Syncytial Virus Drugs
- 10.3.4 Human Respiratory Syncytial Virus Drugs Product Introduction
- 10.3.5 GSK Recent Development
- 10.4 Teva Pharmaceutical
- 10.4.1 Teva Pharmaceutical Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Human Respiratory Syncytial Virus Drugs
- 10.4.4 Human Respiratory Syncytial Virus Drugs Product Introduction
- 10.4.5 Teva Pharmaceutical Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Human Respiratory Syncytial Virus Drugs Sales Channels
- 11.2.2 Human Respiratory Syncytial Virus Drugs Distributors
- 11.3 Human Respiratory Syncytial Virus Drugs Customers
12 Market Forecast
- 12.1 Global Human Respiratory Syncytial Virus Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Type
- 12.3 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Application
- 12.4 Human Respiratory Syncytial Virus Drugs Forecast by Regions
- 12.4.1 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Human Respiratory Syncytial Virus Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Human Respiratory Syncytial Virus Drugs. Industry analysis & Market Report on Human Respiratory Syncytial Virus Drugs is a syndicated market report, published as Global (United States, European Union and China) Human Respiratory Syncytial Virus Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Human Respiratory Syncytial Virus Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
